None listed
Conditions
Interventions
Intervention1: BISOPROLOL: 5mg,10mg 6 MONTHS
Control Intervention1: NIL: NIL
Sponsors
Merck Pte Ltd
3 International Business Park #02-01
Nordic European Centre
Singapore 609927
Merck Serono (Merck Ltd.) Mumbai.
Shiv Sagar Estate '
A'
Dr. Annie Besant Road
Worli, Mumbai 400 018.
Eligibility
Inclusion criteria
Inclusion criteria: Patient aged 18 years old and above Patient diagnosed with essential hypertension Patient has been prescribed Concor® treatment but may or may not have commenced treatment in the last 2 weeks (from the date of signed informed consent) Patient has one of the following medical history prior to Concor® treatment ? Newly diagnosed with essential hypertension with repeated blood pressure measurements of > 140/90, or ? Current or preceding anti-hypertensive therapy does not result in adequate BP control, which requires either the addition of Concor® to the currently prescribed treatment or a change of treatment to Concor®, or ? Experiences adverse reaction with his current or preceding antihypertensive treatment Patient has a HR > 70 at baseline (before starting Concor treatment) Patient is regularly followed-up by/monitored by the investigator for essential hypertension Patient from whom a written informed consent has been obtained
Exclusion criteria
Exclusion criteria: completed >2 weeks of Concor® treatment acute heart failure or during episodes of heart failure decompensation requiring i.v. inotropic therapy cardiogenic shock second or third degree AV block (without a pacemaker) sick sinus syndrome sinoatrial block HR < 70 at baseline (before starting Concor treatment) symptomatic bradycardia currently on HR lowering treatment (for example verapamil, diltiazem, etc.) symptomatic hypotension severe bronchial asthma or severe chronic obstructive pulmonary disease severe forms of peripheral arterial occlusive disease or severe forms of Raynaud's syndrome untreated phaeochromocytoma metabolic acidosis hypersensitivity to Concor® or to any of the excipients. Any contraindication to Concor® according to SmPC
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of patients with a reduction of at least 10 % in HRTimepoint: after 6 months of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of BP at baseline versus end of study assessment Change of the HR and BP at baseline versus end of study assessment in different patient groups: diabetics, non-diabetics, smokers, non-smokers, age < 60 , age > 60 Change of HbA1C and lipids at baseline versus end of study assessment in diabetics, non-diabetics, smokers, non-smokers, age < 60 , age > 60Timepoint: after 6 months of treatment | — |
Countries
China, India, Indonesia, Philippines, Singapore, Viet Nam
Contacts
Public ContactHARDIK PARMAR
HEAD -MEDICAL SERVICES
Outcome results
None listed